Abstract
The development of glycoprotein (GP) IIb-IIIa antagonists is reviewed with particular emphasis on the characteristics of each agent, the pharmacodynamic profile of each agent, results in pivotal clinical trials, and the associated implications. GP IIb-IIIa antagonists have greatest benefit when used as adjunctive therapy during percutaneous coronary intervention (PCI) when the patient has intra-coronary thrombosis. These agents appear to provide greatest benefit when used in combination with heparin. The clinical niche for parenteral GP IIb-IIIa antagonists is evolving but appears to be for patients in transition, such as individuals requiring emergent PCI before oral agents are fully active and for unstable patients requiring transport to PCI centers. Subsequent studies should evaluate the optimal duration of therapy with GP IIb-IIIa antagonists.
Keywords: Platelet, antiplatelet, glycoprotein IIb-IIIa, pharmacodynamics, acute coronary syndromes, hemostasis, Abciximab, pharmacodynamic assessment, Tiofiban, Eptifibatide
Current Drug Targets
Title: Current Issues with Glycoprotein IIb-IIIa Antagonists
Volume: 12 Issue: 12
Author(s): David J. Schneider
Affiliation:
Keywords: Platelet, antiplatelet, glycoprotein IIb-IIIa, pharmacodynamics, acute coronary syndromes, hemostasis, Abciximab, pharmacodynamic assessment, Tiofiban, Eptifibatide
Abstract: The development of glycoprotein (GP) IIb-IIIa antagonists is reviewed with particular emphasis on the characteristics of each agent, the pharmacodynamic profile of each agent, results in pivotal clinical trials, and the associated implications. GP IIb-IIIa antagonists have greatest benefit when used as adjunctive therapy during percutaneous coronary intervention (PCI) when the patient has intra-coronary thrombosis. These agents appear to provide greatest benefit when used in combination with heparin. The clinical niche for parenteral GP IIb-IIIa antagonists is evolving but appears to be for patients in transition, such as individuals requiring emergent PCI before oral agents are fully active and for unstable patients requiring transport to PCI centers. Subsequent studies should evaluate the optimal duration of therapy with GP IIb-IIIa antagonists.
Export Options
About this article
Cite this article as:
J. Schneider David, Current Issues with Glycoprotein IIb-IIIa Antagonists, Current Drug Targets 2011; 12 (12) . https://dx.doi.org/10.2174/138945011797635768
DOI https://dx.doi.org/10.2174/138945011797635768 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Effect of Risk Factor Changes on Peripheral Arterial Disease and Cardiovascular Risk
Current Drug Targets - Cardiovascular & Hematological Disorders Pigment Epithelium-Derived Factor (PEDF) Blocks Angiotensin IIInduced T Cell Proliferation by Suppressing Autocrine Production of Interleukin-2
Medicinal Chemistry Role of Endogenous Androgen Against Insulin Resistance and Athero-sclerosis in Men with Type 2 Diabetes
Current Diabetes Reviews Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage
Current Pharmaceutical Design Recent Advances in Small Animal Cardiac Magnetic Resonance Imaging
Current Cardiology Reviews Reduction of Sympathetic Hyperactivity by Agents that Inhibit the Renin Angiotensin Aldosterone System
Current Hypertension Reviews Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target
Current Medicinal Chemistry Chest Pain, Panic Disorder and Coronary Artery Disease: A Systematic Review
CNS & Neurological Disorders - Drug Targets Nanomedicine: Magnetic Nanoparticles and their Biomedical Applications
Current Medicinal Chemistry Diabetic Bone Fracture Repair: A Progenitor Cell-Based Paradigm
Current Stem Cell Research & Therapy Drug Therapy of Neuropathic Pain: Current Developments and Future Perspectives
Current Drug Targets Potential Use of Vanadium Compounds in Therapeutics
Current Medicinal Chemistry Hypertension and Ischemic Heart Disease in Women
Current Pharmaceutical Design Platelet Microparticles Induce Angiogenesis and Neurogenesis after Cerebral Ischemia
Current Neurovascular Research Novel Imaging Techniques in Acute Kidney Injury
Current Drug Targets Formaldehyde as a trigger for protein aggregation and potential target for mitigation of age-related, progressive cognitive impairment
Current Topics in Medicinal Chemistry Infections and Atheromatous Plaque: Current Therapeutic Implications
Current Pharmaceutical Design Attenuation of Microvascular Injury in Preconditioned Ischemic Myocardium: Imaging with Tc-99m Glucaric Acid and In-111 Human Fibrinogen
Current Molecular Imaging (Discontinued) The Molecular Concept of Atheromatous Plaques
Current Drug Targets Causes and Effects of Cellular Oxidative Stress as a Result of MDMA Abuse
Current Pharmaceutical Biotechnology